Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019693 (
HIV
)
170,526
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In cells infected by
HIV
-1 mutants lacking a functional Vif protein,
APOBEC3G
is specifically packaged into progeny virions and then interferes with the process of virus infection. Here, we show that incorporation of
APOBEC3G
into
HIV
-1 virions is mediated by the specific interaction of
APOBEC3G
with the carboxy-terminal nucleocapsid/p6 domain of the Gag polyprotein precursor. As a result,
HIV
-1 virus-like particles that lack the nucleocapsid domain fail to package
APOBEC3G
. Surprisingly, RNA was also found to be essential for formation of the nucleocapsid--
APOBEC3G
complex in vitro, thus raising the possibility that RNA may form a bridge between these two proteins.
...
PMID:Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. 1546 36
In the human genome the apolipoprotein B mRNA-editing enzyme catalytic polypeptide (APOBEC)3 gene has expanded into a tandem array of genes termed APOBEC3A-G. Two members of this family,
APOBEC3G
and APOBEC3F, have been found to have potent activity against virion infectivity factor deficient (Deltavif) human immunodeficiency virus 1 (HIV-1). These enzymes become encapsidated in Deltavif
HIV
-1 virions and in the next round of infection deaminate the newly synthesized reverse transcripts. The lentiviral Vif protein prevents the deamination by inducing the degradation of
APOBEC3G
and APOBEC3F. We report here that two additional APOBEC3 family members, APOBEC3B and APOBEC3C, have potent antiviral activity against simian immuno-deficiency virus (SIV), but not
HIV
-1. Both enzymes were encapsidated in
HIV
-1 and SIV virions and were active against Deltavif SIV(mac) and SIV(agm). SIV Vif neutralized the antiviral activity of APOBEC3C, but not that of APOBEC3B. APOBEC3B induced abundant G --> A mutations in both wild-type and Deltavif SIV reverse transcripts. APOBEC3C induced substantially fewer mutations. APOBEC3F was found to be active against SIV and sensitive to SIV(mac) Vif. These findings raise the possibility that the different APOBEC3 family members function to neutralize specific lentiviruses.
...
PMID:APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. 1546 72
APOBEC3G
exerts its antiviral activity by targeting to retroviral particles and inducing viral DNA hypermutations in the absence of Vif. However, the mechanism by which
APOBEC3G
is packaged into virions remains unclear. We now report that viral genomic RNA enhances but is not essential for human
APOBEC3G
packaging into human immunodeficiency virus type 1 (HIV-1) virions. Packaging of
APOBEC3G
was also detected in
HIV
-1 Gag virus-like particles (VLP) that lacked all the viral genomic RNA packaging signals. Human
APOBEC3G
could be packaged efficiently into a divergent subtype
HIV
-1, as well as simian immunodeficiency virus, strain mac, and murine leukemia virus Gag VLP. Cosedimentation of human
APOBEC3G
and intracellular Gag complexes was detected by equilibrium density and velocity sucrose gradient analysis. Interaction between human
APOBEC3G
and
HIV
-1 Gag was also detected by coimmunoprecipitation experiments. This interaction did not require p6, p1, or the C-terminal region of NCp7. However, the N-terminal region, especially the first 11 amino acids, of
HIV
-1 NCp7 was critical for
HIV
-1 Gag and
APOBEC3G
interaction and virion packaging. The linker region flanked by the two active sites of human
APOBEC3G
was also important for efficient packaging into
HIV
-1 Gag VLP. Association of human
APOBEC3G
with RNA-containing intracellular complexes was observed. These results suggest that the N-terminal region of
HIV
-1 NC, which is critical for binding to RNA and mediating Gag-Gag oligomerization, plays an important role in
APOBEC3G
binding and virion packaging.
...
PMID:Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. 1547 26
The virus infectivity factor (Vif) is a protein encoded by most primate lentiviruses. Recent evidence suggests that
HIV
-1 Vif reduces the intracellular levels of the host cytidine deaminase
APOBEC3G
(Apo3G) and inhibits its packaging into virions. These functions of Vif are thought to be species-specific. Accordingly,
HIV
-1 Vif can target only human Apo3G (hApo3G), whereas, African green monkey simian immunodeficiency virus (SIVagm) Vif can inhibit African green monkey but not human Apo3G. Consistent with this, we found that SIVagm Vif does not affect the stability of exogenously and endogenously expressed hApo3G and does not prevent packaging of exogenous and endogenous hApo3G into SIVagm virions. Nevertheless, SIVagm Vif supported spreading infection of SIVagm virus in the hApo3G-positive human A3.01 T cell line and rescued infectivity of viruses produced from Apo3G-expressing HeLa cells. Sequence analysis verified that SIVagm Vif inhibited the accumulation of hApo3G-induced mutations, suggesting that SIVagm Vif is indeed active in human cells. Our data suggest that SIVagm Vif can inhibit hApo3G activity without inducing its intracellular degradation or preventing its packaging into virions.
...
PMID:Production of infectious SIVagm from human cells requires functional inactivation but not viral exclusion of human APOBEC3G. 1552 83
To study how
HIV
-1 viral infectivity factor (Vif) mediates proteasome-dependent depletion of host factor
APOBEC3G
, functional and nonfunctional Vif-
APOBEC3G
interactions were correlated with subcellular localization.
APOBEC3G
localized throughout the cytoplasm and co-localized with gamma-tubulin, 20 S proteasome subunit, and ubiquitin at punctate cytoplasmic bodies that can be used to monitor the Vif-
APOBEC3G
interaction in the cell. Through immunostaining and live imaging, we showed that a substantial fraction of Vif localized to the nucleus, and this localization was impaired by deletion of amino acids 12-23. When co-expressed, Vif exhibited more pronounced localization to the cytoplasm and reduced the total cellular levels of
APOBEC3G
but rarely co-localized with
APOBEC3G
at cytoplasmic bodies. On the contrary, Vif(C114S), which is inactive but continues to interact with
APOBEC3G
, stably associated with
APOBEC3G
in the cytoplasm, resulting in complete co-localization at cytoplasmic bodies and a dose-dependent exclusion of Vif(C114S) from the nucleus. Following proteasome inhibition, cytoplasmic
APOBEC3G
levels increased, and both proteins co-accumulated nonspecifically into a vimentin-encaged aggresome. Furthermore in the presence or absence of
APOBEC3G
, Vif localization was significantly altered by proteasome inhibition, suggesting that aberrant localization may also contribute to the loss of Vif function. Finally mutations at Vif Ile(9) disrupted the ability of Vif or Vif(C114S) to coimmunoprecipitate and to co-localize with
APOBEC3G
, suggesting that the N terminus of Vif mediates interactions with
APOBEC3G
. Taken together, these results demonstrate that cytoplasmic Vif-
APOBEC3G
interactions are required but are not sufficient for Vif to modulate
APOBEC3G
and can be monitored by co-localization in vivo.
...
PMID:Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. 1553 45
HIV
-1 Vif (viral infectivity factor) protein overcomes the antiviral activity of the DNA deaminase
APOBEC3G
by targeting it for proteasomal degradation. We report here that Vif targets
APOBEC3G
for degradation by forming an SCF-like E3 ubiquitin ligase containing Cullin 5 and Elongins B and C (Cul5-EloB-EloC) through a novel SOCS (suppressor of cytokine signaling)-box that binds EloC. Vif binding to EloC is negatively regulated by serine phosphorylation in the BC-box motif of the SOCS-box. Vif ubiquitination is promoted by Cul5 in vitro and in vivo, and requires an intact SOCS-box. Thus, autoubiquitination of Vif occurs within the assembled Vif-Cul5 complex, analogous to F-box proteins that are autoubiquitinated within their SCF (Skp1-Cullin-F-box) complex. These findings suggest mechanisms that regulate the assembly and activity of Cul5 E3 complexes through phosphorylation or autoubiquitination of the SOCS-box protein, and identify interactions between Vif and host cell proteins that may be therapeutic targets.
...
PMID:Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. 1557 92
APOBEC3G
, which induces hypermutations in newly synthesized viral DNA, is suppressed by
HIV
-1 Vif, acting through Cul5-ElonginB-ElonginC E3 ubiquitin ligase. We have now characterized a novel SOCS box in
HIV
-1 Vif that mediates its interaction with ElonginC. In this SOCS box, alanine replaces the consensus cysteine in the previously identified SOCS box. This new motif was necessary but insufficient for interaction with Cul5-ElonginB-ElonginC, as two highly conserved Cys residues outside the SOCS box were required to interact with Cul5 but not ElonginC. Therefore, selective assembly with Cul5 versus Cul2 E3 may require protein interfaces besides the SOCS-box-ElonginC interaction.
...
PMID:Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. 1557 93
AIDS has become the greatest pandemic in the human history counting approximately 40 millions people worldwide. To purge
HIV
-1 infection, new therapeutic approaches need to be searched in alternative and/or in addition to the current pharmacological ones. Recently, several independent laboratories have unveiled a non-immune intracellular anti-
HIV
-1 defense strategy based on the cytidine deaminase
APOBEC3G
, which restricts
HIV
-1 production by directly mutating the proviral DNA in infected cells. To counteract this defense pathway,
HIV
-1 has developed an evasion strategy by acquiring the accessory protein Vif, which blocks the action of
APOBEC3G
by inducing its proteasome-mediated degradation.
...
PMID:Blocking HIV-1 Vif restores a natural mechanism of intracellular antiviral defense. 1557 76
APOBEC3G
is a cytidine deaminase that limits the replication of many retroviruses. This antiviral host factor is packaged into retrovirus particles, where it targets single-stranded DNA generated during reverse transcription and induces up to 2% of G-to-A mutations, which are lethal for the
HIV
-1 provirus. Vif protein counteracts this antiviral factor by decreasing its packaging into lentivirus particles. Here, we demonstrate that Nedd4-1, an HECT E3 ubiquitin ligase, interacts with
APOBEC3G
, through its WW2 and WW3 domains. As a result of this interaction,
APOBEC3G
undergoes post-translational modification by addition of ubiquitin moieties. Accordingly, we demonstrate that the dominant negative Nedd4-1 C/S form prevents
APOBEC3G
ubiquitination. Moreover, the packaging of
APOBEC3G
into Pr55 Gag virus-like particles and into
HIV
-1 virions is reduced when Nedd4-1 C/S is expressed. During
HIV
-1 viral production in the presence of
APOBEC3G
, Nedd4-1 C/S restores partially the infectivity of Deltavif
HIV
-1. We conclude that the ubiquitination of
APOBEC3G
by Nedd4-1 favors its targeting to the virus assembly site where
APOBEC3G
interacts with Gag and is packaged into
HIV
-1 particles in the absence of Vif.
...
PMID:APOBEC3G ubiquitination by Nedd4-1 favors its packaging into HIV-1 particles. 1558 98
CEM15 (or
APOBEC3G
) has recently been identified as an inhibitor of human immunodeficiency virus type 1 (HIV-1) replication in vitro. To evaluate the impact of its genetic variations on the progression of acquired immunodeficiency syndrome (AIDS), we have performed an extensive genetic analysis of CEM15. We have sequenced CEM15 in a cohort of 327
HIV
-1-seropositive patients with extreme disease progression phenotypes--either slow progression or rapid progression--and in 446 healthy control subjects, all of white descent. We have identified 29 polymorphisms with allele frequencies >1%, 14 of which were newly characterized. There were no significant associations between the polymorphisms or haplotypes of CEM15 and a disease progression phenotype in our cohort.
...
PMID:Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. 1560 24
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>